

Ruben Pio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5665280/publications.pdf>

Version: 2024-02-01

129
papers

6,471
citations

53794

45
h-index

76900

74
g-index

133
all docs

133
docs citations

133
times ranked

9407
citing authors

#	ARTICLE	IF	CITATIONS
1	Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges. <i>Journal of Thoracic Oncology</i> , 2019, 14, 343-357.	1.1	306
2	Alternative splicing: an emerging topic in molecular and clinical oncology. <i>Lancet Oncology</i> , The, 2007, 8, 349-357.	10.7	230
3	Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. <i>Human Mutation</i> , 2008, 29, 617-622.	2.5	226
4	Hypoxia-Inducible Factor-1 (HIF-1) Up-Regulates Adrenomedullin Expression in Human Tumor Cell Lines during Oxygen Deprivation: A Possible Promotion Mechanism of Carcinogenesis. <i>Molecular Endocrinology</i> , 2000, 14, 848-862.	3.7	221
5	Anaphylatoxin C5a Creates a Favorable Microenvironment for Lung Cancer Progression. <i>Journal of Immunology</i> , 2012, 189, 4674-4683.	0.8	219
6	Complement Factor H Is a Serum-binding Protein for Adrenomedullin, and the Resulting Complex Modulates the Bioactivities of Both Partners. <i>Journal of Biological Chemistry</i> , 2001, 276, 12292-12300.	3.4	214
7	A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and Metastasis. <i>Cancer Discovery</i> , 2017, 7, 694-703.	9.4	160
8	The Role of Complement in Tumor Growth. <i>Advances in Experimental Medicine and Biology</i> , 2014, 772, 229-262.	1.6	155
9	Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer. <i>Lung Cancer</i> , 2003, 41, 131-143.	2.0	138
10	Complementing the Cancer-Immunity Cycle. <i>Frontiers in Immunology</i> , 2019, 10, 774.	4.8	136
11	Investigation of Complement Activation Product C4d as a Diagnostic and Prognostic Biomarker for Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1385-1393.	6.3	127
12	Complement inhibition in cancer therapy. <i>Seminars in Immunology</i> , 2013, 25, 54-64.	5.6	121
13	A gene-alteration profile of human lung cancer cell lines. <i>Human Mutation</i> , 2009, 30, 1199-1206.	2.5	113
14	A Novel Epigenetic Signature for Early Diagnosis in Lung Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3361-3371.	7.0	113
15	Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene. <i>Oncogene</i> , 2004, 23, 4037-4040.	5.9	111
16	Expression of Complement Factor H by Lung Cancer Cells. <i>Cancer Research</i> , 2004, 64, 6310-6318.	0.9	108
17	Innate immune mediators in cancer: between defense and resistance. <i>Immunological Reviews</i> , 2016, 274, 290-306.	6.0	104
18	The Effects of Adrenomedullin Overexpression in Breast Tumor Cells. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1226-1237.	6.3	103

#	ARTICLE	IF	CITATIONS
19	Improving Selection Criteria for Lung Cancer Screening. The Potential Role of Emphysema. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 924-931.	5.6	90
20	Complement anaphylatoxins C3a and C5a: Emerging roles in cancer progression and treatment. Seminars in Cell and Developmental Biology, 2019, 85, 153-163.	5.0	89
21	Down-Regulation of Human Complement Factor H Sensitizes Non-Small Cell Lung Cancer Cells to Complement Attack and Reduces In Vivo Tumor Growth. Journal of Immunology, 2007, 178, 5991-5998.	0.8	87
22	Molecular Analysis of a Multistep Lung Cancer Model Induced by Chronic Inflammation Reveals Epigenetic Regulation of p16, Activation of the DNA Damage Response Pathway. Neoplasia, 2007, 9, 840-IN12.	5.3	86
23	Strategies to design clinical studies to identify predictive biomarkers in cancer research. Cancer Treatment Reviews, 2017, 53, 79-97.	7.7	80
24	Expression of Sirtuin 1 and 2 Is Associated with Poor Prognosis in Non-Small Cell Lung Cancer Patients. PLoS ONE, 2015, 10, e0124670.	2.5	79
25	Identification of Alternative Splicing Events Regulated by the Oncogenic Factor SRSF1 in Lung Cancer. Cancer Research, 2014, 74, 1105-1115.	0.9	77
26	Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis by CXCL16-mediated Effects. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1164-1176.	5.6	77
27	Assessment of Epidermal Growth Factor Receptor and K-Ras Mutation Status in Cytological Stained Smears of Non-Small Cell Lung Cancer Patients: Correlation with Clinical Outcomes. Oncologist, 2011, 16, 877-885.	3.7	75
28	Adrenomedullin Is a Cross-Talk Molecule that Regulates Tumor and Mast Cell Function during Human Carcinogenesis. American Journal of Pathology, 2006, 168, 280-291.	3.8	74
29	Hypoxia-Inducible Factor-1 (HIF-1) Up-Regulates Adrenomedullin Expression in Human Tumor Cell Lines during Oxygen Deprivation: A Possible Promotion Mechanism of Carcinogenesis. Molecular Endocrinology, 2000, 14, 848-862.	3.7	72
30	Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo. Molecular Cancer, 2010, 9, 139.	19.2	69
31	Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade. Nature Cancer, 2020, 1, 75-85.	13.2	68
32	Adrenomedullin Binding Protein in the Plasma of Multiple Species: Characterization by Radioligand Blotting. Endocrinology, 1999, 140, 4908-4911.	2.8	67
33	Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors. Molecular Immunology, 2008, 45, 169-179.	2.2	67
34	Overexpression of TMPRSS4 in non-small cell lung cancer is associated with poor prognosis in patients with squamous histology. British Journal of Cancer, 2011, 105, 1608-1614.	6.4	64
35	Relative amounts of antagonistic splicing factors, hnRNP A1 and ASF/SF2, change during neoplastic lung growth: Implications for pre-mRNA processing. Molecular Carcinogenesis, 2004, 41, 187-196.	2.7	63
36	Expression of Tumor-Derived Vascular Endothelial Growth Factor and Its Receptors Is Associated With Outcome in Early Squamous Cell Carcinoma of the Lung. Journal of Clinical Oncology, 2012, 30, 1129-1136.	1.6	63

#	ARTICLE	IF	CITATIONS
37	TGFBI expression is associated with a better response to chemotherapy in NSCLC. <i>Molecular Cancer</i> , 2010, 9, 130.	19.2	61
38	A large-scale analysis of alternative splicing reveals a key role of QKI in lung cancer. <i>Molecular Oncology</i> , 2016, 10, 1437-1449.	4.6	60
39	Is adrenomedullin a causal agent in some cases of type 2 diabetes?. <i>Peptides</i> , 1999, 20, 1471-1478.	2.4	59
40	TRAP1 Regulates Proliferation, Mitochondrial Function, and Has Prognostic Significance in NSCLC. <i>Molecular Cancer Research</i> , 2014, 12, 660-669.	3.4	59
41	Cribado de c�ncer de pulm�n: catorce a�os de experiencia del Programa Internacional de Detecci�n Precoz de C�ncer de Pulm�n con TBDR de Pamplona (P-IELCAP). <i>Archivos De Bronconeumolog�a</i> , 2015, 51, 169-176.	0.8	59
42	VEGF121b and VEGF165b are weakly angiogenic isoforms of VEGF-A. <i>Molecular Cancer</i> , 2010, 9, 320.	19.2	55
43	Alternative Splicing in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2009, 4, 674-678.	1.1	52
44	Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis. <i>Cancer Letters</i> , 2022, 529, 70-84.	7.2	51
45	YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 888-899.	5.6	50
46	Identification of Novel Deregulated RNA Metabolism-Related Genes in Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2012, 7, e42086.	2.5	48
47	Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies. <i>Journal of Thoracic Oncology</i> , 2016, 11, 524-536.	1.1	48
48	Inhibitor of Differentiation-1 as a Novel Prognostic Factor in NSCLC Patients with Adenocarcinoma Histology and Its Potential Contribution to Therapy Resistance. <i>Clinical Cancer Research</i> , 2011, 17, 4155-4166.	7.0	47
49	Adrenomedullin functions as an important tumor survival factor in human carcinogenesis. <i>Microscopy Research and Technique</i> , 2002, 57, 110-119.	2.2	46
50	The Oncoprotein SF2/ASF Promotes Non-Small Cell Lung Cancer Survival by Enhancing Survivin Expression. <i>Clinical Cancer Research</i> , 2010, 16, 4113-4125.	7.0	46
51	Endogenous Retroelement Activation by Epigenetic Therapy Reverses the Warburg Effect and Elicits Mitochondrial-Mediated Cancer Cell Death. <i>Cancer Discovery</i> , 2021, 11, 1268-1285.	9.4	42
52	SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation. , 2021, 9, e001496.		42
53	Identification of Importin 8 (IPO8) as the most accurate reference gene for the clinicopathological analysis of lung specimens. <i>BMC Molecular Biology</i> , 2008, 9, 103.	3.0	40
54	Complement C4d-specific antibodies for the diagnosis of lung cancer. <i>Oncotarget</i> , 2018, 9, 6346-6355.	1.8	39

#	ARTICLE	IF	CITATIONS
55	Monocyte Inducible Nitric Oxide Synthase in Multiple Sclerosis: Regulatory Role of Nitric Oxide. <i>Nitric Oxide - Biology and Chemistry</i> , 1997, 1, 95-104.	2.7	38
56	Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value. <i>Tumor Biology</i> , 2016, 37, 13687-13694.	1.8	37
57	Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors. <i>Annals of Oncology</i> , 2020, 31, 274-282.	1.2	36
58	Hypoxia increases susceptibility of non-small cell lung cancer cells to complement attack. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1771-1780.	4.2	34
59	Silica-induced Chronic Inflammation Promotes Lung Carcinogenesis in the Context of an Immunosuppressive Microenvironment. <i>Neoplasia</i> , 2013, 15, 913-918.	5.3	33
60	Phosphorylated tubulin adaptor protein CRMP2 as prognostic marker and candidate therapeutic target for NSCLC. <i>International Journal of Cancer</i> , 2013, 132, 1986-1995.	5.1	32
61	Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer. <i>International Journal of Cancer</i> , 2019, 145, 1991-2001.	5.1	32
62	EventPointer: an effective identification of alternative splicing events using junction arrays. <i>BMC Genomics</i> , 2016, 17, 467.	2.8	31
63	The oncogenic RNA-binding protein SRSF1 regulates LIG1 in non-small cell lung cancer. <i>Laboratory Investigation</i> , 2018, 98, 1562-1574.	3.7	30
64	Tumour-associated macrophages in nonsmall cell lung cancer: the role of interleukin-10. <i>European Respiratory Journal</i> , 2007, 30, 608-610.	6.7	29
65	A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients. <i>Journal of Pathology</i> , 2018, 245, 421-432.	4.5	29
66	Epigenetic alterations leading to TMRSS4 promoter hypomethylation and protein overexpression predict poor prognosis in squamous lung cancer patients. <i>Oncotarget</i> , 2016, 7, 22752-22769.	1.8	29
67	Presence of immunoreactive adrenomedullin in human and bovine milk. <i>Peptides</i> , 2000, 21, 1859-1863.	2.4	28
68	Lung Cancer Screening: Fourteen Year Experience of the Pamplona Early Detection Program (P-IELCAP). <i>Archivos De Bronconeumologia</i> , 2015, 51, 169-176.	0.8	28
69	Expression of the adrenomedullin binding protein, complement factor H, in the pancreas and its physiological impact on insulin secretion. <i>Journal of Endocrinology</i> , 2001, 170, 503-511.	2.6	27
70	hCP-4, Encoded by a Putative Tumor Suppressor Gene at 3p21, But Not Its Alternative Splice Variant hCP-4a, Is Underexpressed in Lung Cancer. <i>Cancer Research</i> , 2004, 64, 4171-4179.	0.9	27
71	Complement Factor H Is Elevated in Bronchoalveolar Lavage Fluid and Sputum from Patients with Lung Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2665-2672.	2.5	27
72	Complement activation product C4d in oral and oropharyngeal squamous cell carcinoma. <i>Oral Diseases</i> , 2015, 21, 899-904.	3.0	27

#	ARTICLE	IF	CITATIONS
73	SPACE: an algorithm to predict and quantify alternatively spliced isoforms using microarrays. <i>Genome Biology</i> , 2008, 9, R46.	9.6	26
74	Underlying Disease Stress Augments Plasma and Tissue Adrenomedullin (AM) Responses to Endotoxin: Colocalized Increases in AM and Inducible Nitric Oxide Synthase within Pancreatic Islets ¹ . <i>Endocrinology</i> , 1999, 140, 5402-5411.	2.8	25
75	Development of a novel splice array platform and its application in the identification of alternative splice variants in lung cancer. <i>BMC Genomics</i> , 2010, 11, 352.	2.8	25
76	Adrenomedullin Binding Protein in the Plasma of Multiple Species: Characterization by Radioligand Blotting. <i>Endocrinology</i> , 1999, 140, 4908-4911.	2.8	25
77	Pharmacokinetics and antitumor efficacy of paclitaxel-cyclodextrin complexes loaded in mucus-penetrating nanoparticles for oral administration. <i>Nanomedicine</i> , 2014, 9, 2109-2121.	3.3	23
78	Complement in Metastasis: A Comp in the Camp. <i>Frontiers in Immunology</i> , 2019, 10, 669.	4.8	23
79	Molecular biomarkers in early stage lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 1165-1185.	2.8	23
80	Elevated Levels of the Complement Activation Product C4d in Bronchial Fluids for the Diagnosis of Lung Cancer. <i>PLoS ONE</i> , 2015, 10, e0119878.	2.5	23
81	Targeting of TMPRSS4 sensitizes lung cancer cells to chemotherapy by impairing the proliferation machinery. <i>Cancer Letters</i> , 2019, 453, 21-33.	7.2	22
82	Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer. <i>Cancer Discovery</i> , 2022, 12, 1356-1377.	9.4	22
83	Combination of a TLR4 ligand and anaphylatoxin C5a for the induction of antigen-specific cytotoxic T cell responses. <i>Vaccine</i> , 2012, 30, 2848-2858.	3.8	21
84	TGFBI expression is an independent predictor of survival in adjuvant-treated lung squamous cell carcinoma patients. <i>British Journal of Cancer</i> , 2014, 110, 1545-1551.	6.4	21
85	Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype. <i>EMBO Molecular Medicine</i> , 2014, 6, 539-550.	6.9	21
86	Expression of p21 inhibits cell cycle progression and suppresses tumorigenicity of lung cancer cells. <i>International Journal of Cancer</i> , 2008, 122, 1512-1520.	5.1	20
87	Comparison of RNA-seq and microarray platforms for splice event detection using a cross-platform algorithm. <i>BMC Genomics</i> , 2018, 19, 703.	2.8	20
88	Identification, characterization, and physiological actions of factor H as an adrenomedullin binding protein present in human plasma. <i>Microscopy Research and Technique</i> , 2002, 57, 23-27.	2.2	19
89	Overexpression of adrenomedullin gene markedly inhibits proliferation of PC3 prostate cancer cells in vitro and in vivo. <i>Molecular and Cellular Endocrinology</i> , 2003, 199, 179-187.	3.2	19
90	Telomere length, COPD and emphysema as risk factors for lung cancer. <i>European Respiratory Journal</i> , 2017, 49, 1601521.	6.7	19

#	ARTICLE	IF	CITATIONS
91	Mapping of the Adrenomedullin-Binding Domains in Human Complement Factor H. Hypertension Research, 2003, 26, S55-S59.	2.7	19
92	The sVEGFR1-i13 splice variant regulates a β 1 integrin/VEGFR autocrine loop involved in the progression and the response to anti-angiogenic therapies of squamous cell lung carcinoma. British Journal of Cancer, 2018, 118, 1596-1608.	6.4	18
93	Molecular Profiling of Computed Tomography Screen-Detected Lung Nodules Shows Multiple Malignant Features. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 373-380.	2.5	17
94	TMPRSS4: A Novel Tumor Prognostic Indicator for the Stratification of Stage IA Tumors and a Liquid Biopsy Biomarker for NSCLC Patients. Journal of Clinical Medicine, 2019, 8, 2134.	2.4	17
95	Targeted depletion of <i>PIK3R2</i> induces regression of lung squamous cell carcinoma. Oncotarget, 2016, 7, 85063-85078.	1.8	16
96	Molecular characterization of small peripheral lung tumors based on the analysis of fine needle aspirates. Histology and Histopathology, 2008, 23, 33-40.	0.7	16
97	EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration. European Respiratory Journal, 2009, 34, 1477-1486.	6.7	15
98	A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer. Translational Research, 2021, 233, 77-91.	5.0	15
99	The Role of Adrenomedullin as a Growth Regulatory Peptide in the Normal and Malignant Setting. Journal of Animal Science, 1999, 77, 55.	0.5	15
100	New syngeneic inflammatory-related lung cancer metastatic model harboring double KRAS/WWOX alterations. International Journal of Cancer, 2014, 135, 2516-27.	5.1	14
101	Multiscale in situ analysis of the role of dyskerin in lung cancer cells. Integrative Biology (United Kingdom), 2013, 5, 107-114.	1.3	13
102	Identification of a novel synthetic lethal vulnerability in non-small cell lung cancer by co-targeting TMPRSS4 and DDR1. Scientific Reports, 2019, 9, 15400.	3.3	13
103	Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations. BMC Genomics, 2015, 16, 752.	2.8	12
104	Current challenges in lung cancer early detection biomarkers. European Journal of Cancer, 2009, 45, 377-378.	2.8	11
105	Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer. Cancer Medicine, 2018, 7, 3474-3483.	2.8	11
106	Cancer and diabetes: two pathological conditions in which adrenomedullin may be involved. Peptides, 2001, 22, 1719-1729.	2.4	10
107	Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators. European Journal of Cancer, 2015, 51, 1897-1903.	2.8	10
108	Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8+ T Cells. Cancers, 2020, 12, 3169.	3.7	10

#	ARTICLE	IF	CITATIONS
109	Persistence of High Levels of Serum Complement C5a in Severe COVID-19 Cases After Hospital Discharge. <i>Frontiers in Immunology</i> , 2021, 12, 767376.	4.8	10
110	Smokers with CT Detected Emphysema and No Airway Obstruction Have Decreased Plasma Levels of EGF, IL-15, IL-8 and IL-1ra. <i>PLoS ONE</i> , 2013, 8, e60260.	2.5	9
111	5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging. <i>Thorax</i> , 2019, 74, 371-379.	5.6	9
112	Surgical Outcomes in a Lung Cancer-Screening Program Using Low Dose Computed Tomography. <i>Archivos De Bronconeumologia</i> , 2021, 57, 101-106.	0.8	9
113	“Stealth” corporate innovation: an emerging threat for therapeutic drug development. <i>Nature Immunology</i> , 2019, 20, 1409-1413.	14.5	7
114	Prognostic signature of early lung adenocarcinoma based on the expression of ribonucleic acid metabolism-related genes. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2015, 150, 986-992.e11.	0.8	6
115	DrugSniper, a Tool to Exploit Loss-Of-Function Screens, Identifies CREBBP as a Predictive Biomarker of VOLASERTIB in Small Cell Lung Carcinoma (SCLC). <i>Cancers</i> , 2020, 12, 1824.	3.7	6
116	Nitric Oxide Activates Granule-Associated DNase in Human Monocytes. <i>Nitric Oxide - Biology and Chemistry</i> , 1998, 2, 165-173.	2.7	5
117	The Complement System in Ovarian Cancer: An Underexplored Old Path. <i>Cancers</i> , 2021, 13, 3806.	3.7	5
118	Underlying Disease Stress Augments Plasma and Tissue Adrenomedullin (AM) Responses to Endotoxin: Colocalized Increases in AM and Inducible Nitric Oxide Synthase within Pancreatic Islets. <i>Endocrinology</i> , 1999, 140, 5402-5411.	2.8	5
119	Two cell line models to study multiorgan metastasis and immunotherapy in lung squamous cell carcinoma. <i>DMM Disease Models and Mechanisms</i> , 2022, 15, .	2.4	5
120	Design and validation of a tunable inertial microfluidic system for the efficient enrichment of circulating tumor cells in blood. <i>Bioengineering and Translational Medicine</i> , 2022, 7, .	7.1	5
121	Granule associated DNase in T4 and T8 lymphocytes from patients with autoimmune diseases. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 1998, 1406, 51-61.	3.8	3
122	Whole exome sequencing characterization of individuals presenting extreme phenotypes of high and low risk of developing tobacco-induced lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2021, 10, 1327-1337.	2.8	3
123	Assessment of EGF receptor ligand expression in gastric carcinoma and in lesional skin of paraneoplastic acanthosis nigricans: a case report. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e301-e302.	2.4	2
124	Editorial: The Role of Complement in Tumors. <i>Frontiers in Immunology</i> , 2020, 11, 139.	4.8	2
125	Adrenomedullin: An Esoteric Juggernaut of Human Cancers. , 2006, , 453-458.		2
126	MA17.10 YES1 Kinase is a New Therapeutic Target in Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, S446-S447.	1.1	1

#	ARTICLE	IF	CITATIONS
127	Abstract 2477: Max inactivation in small cell lung cancer disrupts the MYC-SWI/SNF programs and is synthetic lethal with BRG1. , 2014, , .		1
128	Abstract LB-117: Dasatinib for the treatment of patients with non-small cell lung cancer harboring YES1 amplification. , 2017, , .		1
129	Abstract LB-084: Dasatinib reduces tumor growth in xenograft models derived from human lung tumors with YES1 overexpression. , 2018, , .		1